NCT03186482View on ClinicalTrials.gov

RIFT: Effect of Rifampicin on Plasma PK of FTC, TAF and Intracellular TFV-DP & FTC-TP

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

January 10, 2018

Study Completion Date

January 10, 2018

Conditions
HIV
Interventions
DRUG

Descovy® (TAF/FTC)

25/200 mg once daily for 28 days (DAYS 1-28).

DRUG

Viread® (TDF)

245 mg once daily for 28 days (DAYS 57-84).

DRUG

Rifadin® (Rifampicin)

600 mg once daily for 28 days (DAYS 29-56).

Trial Locations (1)

SW10 9NH

Chelsea and Westminster Hospital NHS Foundation Trust, London

All Listed Sponsors
lead

St. Stephens Clinical Research

OTHER

NCT03186482 - RIFT: Effect of Rifampicin on Plasma PK of FTC, TAF and Intracellular TFV-DP & FTC-TP | Biotech Hunter | Biotech Hunter